Compare Fiverr International Ltd (FVRR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Spyre Therapeutics Inc. Common Stock — how do they compare? Fiverr International Ltd trades at $8.56 (market cap $307.38M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 23.9× Fiverr International Ltd's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FVRR | SYRE | |
|---|---|---|
Market Cap | $307.38M | $7.35B |
Volume | 937,489 | 1,624,631 |
Sector | Media | Health |
52-Week High | $23.60 | $108.92 |
52-Week Low | $8.47 | $22.18 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $59.76M | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.60, down 0.23% with a bearish technical signal. The company shows improving fundamentals with revenue growth from $391M in 2024 to $431M in 2025 and net income margin expanding to 7.18%. Recent Q2 2026 earnings missed expectations, and AI disruption is compressing demand for lower-value freelance work. Analyst consensus is cautious with 76% hold ratings despite attractive valuation multiples including P/E of 10.56 and P/S of 0.75.
The outlook remains challenged by AI-driven market shifts, though current valuations appear discounted. Key risks include sustained revenue pressure from AI adoption and competitive threats. Upside potential exists if Fiverr successfully adapts its platform to the evolving gig economy, with analyst price targets suggesting 22% upside to the $10.50 consensus.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
